Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VSTM vs RGNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VSTM Captures Overall Composite Edge (56.9 HOLD vs 45.3 HOLD), While RGNX Leads 4–2 on Growth & Valuation Pillars
VSTM Overall Winner
6-Pillar Tally: VSTM 2 – 4 RGNX
Matrix Metrics: VSTM 5 – 3 RGNX
As of Nov 16, 2026, Verastem, Inc. (VSTM) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (56.9/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. VSTM trades at $7.89 (N/M Forward P/E, -193.7% operating margin) versus RGNX at $7.45 (N/M Forward P/E, -120.4% operating margin).
- Growth vs. Quality Trade-Off: VSTM earns the overall head-to-head edge with a stronger Unified Composite Score (56.9/100 HOLD vs. RGNX 45.3/100 HOLD) and 1.11β · 72% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: VSTM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VSTM vs RGNX
VSTM
Head-to-Head Winner
Verastem, Inc.
$7.89
-3.48% 1D
Market Cap
$1.1B
TTM Revenue
$100M
Forward P/E
N/M
Beta / 30D Vol
1.11β · 72% Vol
Unified Composite Score
56.9
HOLD
Tech 33.0
Fund 51.0
Flow 64.0
Mom 70.0
Weinstein Technical Phase
Neutral · Hold
RGNX
REGENXBIO Inc.
$7.45
-2.49% 1D
Market Cap
$500.9M
TTM Revenue
$154M
Forward P/E
N/M
Beta / 30D Vol
1.82β · 76% Vol
Unified Composite Score
45.3
HOLD
Tech 36.0
Fund 44.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (VSTM 2 – 4 RGNX)
1. Valuation Multiples
RGNX
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
0.26x
EV / Revenue
10.2x
3.1x
2. Growth & Scale
VSTM
Revenue Growth (YoY)
+113.6%
-69.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$100M
$154M
Market Cap
$1.1B
$500.9M
3. Profitability & Quality
RGNX
Gross Margin
87.2%
-64.5%
Operating Margin
-193.7%
-120.4%
Net Profit Margin
-178.4%
-113.9%
Return on Equity (ROE)
-471.2%
-113.2%
4. Balance Sheet & Cash Flow
RGNX
Cash Generation (TTM)
-$168M
-$155M
Cash Flow Margin
N/A
-100.6%
Net Cash / Leverage
$44M Net Cash
$29M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
VSTM
Options Structure Phase
CONSOLIDATION
BREAKDOWN
Current IV / %ile
96.8% (10th %ile)
349.6% (52nd %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat
RGNX
OpEx & R&D Intensity
N/A
55.9% of Rev ($86M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VSTM (5) vs RGNX (3)| Institutional Metric | VSTM | RGNX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.1B | $500.9M | VSTM | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +113.6% | -69.2% | VSTM | |
| Operating Margin (TTM) | -193.7% | -120.4% | RGNX | |
| Net Profit Margin | -178.4% | -113.9% | RGNX | |
| Return on Equity (ROE) | -471.2% | -113.2% | RGNX | |
| 52-Week Range Position | 60% ($3–$11) | 19% ($5–$16) | VSTM | |
| Beta / 30D Volatility | 1.11β · 72% Vol | 1.82β · 76% Vol | VSTM | |
| Unified Institutional Score | 56.9 / 100 (HOLD) | 45.3 / 100 (HOLD) | VSTM | |
| Trailing 12M Revenue (USD) | $100M | $154M | Scale | |
| Gross Profit Margin (TTM) | 87.2% | -64.5% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 10.2x EV/Rev | 0.26x PEG · 3.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$168M ($44M Net Cash) | -$155M ($29M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
RGNX +16.31 pp
3M Horizon
VSTM +38.96 pp
6M Horizon
VSTM +53.47 pp
1Y Horizon
VSTM +33.35 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VSTM Revenue | RGNX Revenue | VSTM Op. Margin | RGNX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $30M | $220M | -354.8% | 40.3% | RGNX |
| FY2019 | $20M | $40M | -758.1% | -422.9% | RGNX |
| FY2020 | $90M | $150M | -55.8% | -77.1% | VSTM |
| FY2021 | $0M | $470M | -2991.2% | 34.0% | RGNX |
| FY2022 | $0M | $110M | -2809.6% | -233.2% | RGNX |
| FY2023 | N/A | $90M | N/A | -297.1% | RGNX |
| FY2024 | $10M | $80M | -1149.6% | -280.0% | RGNX |
| FY2025 | $30M | $170M | -550.3% | -94.6% | RGNX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VSTM
CONSOLIDATION
Current IV
96.8%
IV Percentile
10th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact VSTM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
RGNX
BREAKDOWN
Current IV
349.6%
IV Percentile
52nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VSTM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
RGNX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
55.9% of Rev ($86M)
90D Engineering Disclosures
0 Published
Investor FAQ VSTM vs RGNX Key Questions & Quantitative Answers
As of Nov 16, 2026, Verastem, Inc. (VSTM) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (56.9/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. VSTM trades at $7.89 (N/M Forward P/E, -193.7% operating margin) versus RGNX at $7.45 (N/M Forward P/E, -120.4% operating margin). Growth vs. Quality Trade-Off: VSTM earns the overall head-to-head edge with a stronger Unified Composite Score (56.9/100 HOLD vs. RGNX 45.3/100 HOLD) and 1.11β · 72% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VSTM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VSTM leads the Growth & Scale pillar: VSTM posts +113.6% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (87.2% gross margin, -193.7% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VSTM cumulative revenue shifted +0.0% while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, VSTM deploys N/A (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.
RGNX screens cheaper on headline valuation multiples. VSTM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 10.2x EV/Revenue (unreported FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VSTM (-471.2% ROE) versus RGNX (-113.2% ROE) capital efficiency.
In options market volatility and institutional positioning, VSTM carries 96.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.11β · 72% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
RGNX vs VSTM · Reverse Pair
VSTM vs VTVT
· Sector Peer
VSTM vs RIGL
· Sector Peer
RGNX vs QURE
· Sector Peer
RGNX vs MGTX
· Sector Peer
RGNX vs RARE
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem